BIS Research Study Highlights the Global MRD Market to Reach $1.61 Billion by 2025

BIS Research Study Highlights the Global MRD Market to Reach $1.61 Billion by 2025

PR Newswire

FREMONT, Calif., Jan. 13, 2021

FREMONT, Calif., Jan. 13, 2021 /PRNewswire/ -- The premium market intelligence report published by BIS Research on the title Global MRD Testing Market highlights that the market is projected to reach $1.61 billion by 2025. The study also highlights that the market is set to witness a CAGR of 15.64% during the period between 2020 and 2025. The growth is aided by factors including increasing research funding from the National Cancer Institute and rising incidence of hematologic malignancies, among others.

BIS Research Logo

Minimal residual disease (MRD) testing is an evolving testing regimen that has been driving initiatives in the management of hematological malignancy patients. It is currently one of the fastest-growing markets under the molecular diagnostics umbrella. MRD testing promises the integration of evolutionary molecular technologies into hematological malignancy care regimens, thereby driving tremendous growth in the overall hematological malignancies testing market.

The detailed study is a compilation of 12 Market Data Tables and 196 Figures spread through 262 Pages and in-depth TOC on "Global MRD Testing Market"

The comprehensive study covers the following:

The report is beneficial for

View the Report from BIS Research: Global MRD Testing Market

The premium market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as the potential long-term cost savings, increasing market access in the emerging economies, and technological evolution of testing, among others.

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include types of technologies used, application areas, end users, and regions. The application and the region segment have been further sub-segmented to offer an in-depth analysis of the global MRD testing market.

The technology and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of preferred assays and panels.  Pertaining to the market segmentation, the technology segment is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies. The application segment has been segmented into hematologic malignancies and solid tumors.

Request for a Sample:

Hematologic malignancies have been further sub-segmented into non-Hodgkin's lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, and other leukemia. Further, the end user segment has been further segmented into specialty clinics and hospitals, diagnostic laboratories, research institutions, and other end users.

Emphasizing the dominance of the North America region in the global MRD testing market, Nitish Kumar Singh, Lead Analyst – BIS Research states, "In North America, several emerging and legacy diagnostics manufacturers are focusing on expanding their MRD testing product portfolio and are actively involved in developing products based on new technologies to offer reliable clinical outcomes, particularly for patients suffering from hematologic malignancies. Moreover, the recent FDA-approvals received by clonoSEQ and Signatera have revolutionized the utilization of NGS for MRD analysis, as these companies now look to enter international markets."

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include ICON plc, ArcherDX, Inc., ARUP Laboratories, ASURAGEN INC., Cergentis B.V., Bio-Rad Laboratories, Inc., Mission Bio, Inc. Guardant Health, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Inivata Ltd., Natera, Inc., NeoGenomics Laboratories, Inc., Opko Health, Inc., Quest Diagnostics Incorporated, and Sysmex Corporation.

For Custom Research Services in MRD Testing Market:

How can market intelligence on MRD testing add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies take Strategic Decisions

BIS Research Related Market Studies:

Global Hematologic Malignancies Testing Market – Analysis and Forecast, 2018-2025

Global Tumor Genomics Market – Analysis and Forecast, 2019-2028

About BIS Research: 

BIS Research, a premium market intelligence company offers in-depth insights and consulting to Fortune 500 companies. We are established and known for tracking the growth of deep technologies across key industry verticals and the subsequent challenges and opportunities associated with deep tech across markets, applications and products.

With more than 500 clients, over 7000 plus primary interviews and approximately 200 reports published in a year BIS Research has set an interesting growth trajectory for itself. We provide market estimations, emerging high-growth applications, technology analysis, highly segmented granular country-level market data, and other important market parameters that come in handy for our clients during strategic decision-making.

We publish a wide gamut of syndicated market studies across industry verticals. In addition, bespoke market studies is another area where BIS Research excels at along with consulting services.

BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, MRD testing, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 5 years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in precision medicine on its Insight Monk platform for the past two years successfully.  


Bhavya Banga
BIS Research Inc.
FREMONT CA 94538-1686
Visit our Blog @ 
Connect with us on LinkedIn @ 
Connect with us on Twitter@ 


Voltar noticias em Inglês